Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2011 1
2013 1
2015 1
2017 2
2018 3
2019 1
2020 3
2021 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Choueiri TK, et al. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851. N Engl J Med. 2023. PMID: 37163623 Free PMC article. Clinical Trial.
Approach of the patient with renal cancer: Is there a collaboration between urology and oncology?
Sabell Pérez-Salgado F, Vázquez-Estévez S, Anido-Herranz U, Blanco-Parra M, Casas-Nebra FJ, Fernández-Calvo O, Lázaro-Quintela M, López-García S. Sabell Pérez-Salgado F, et al. Among authors: anido herranz u. Actas Urol Esp (Engl Ed). 2018 Jan-Feb;42(1):1-4. doi: 10.1016/j.acuro.2017.04.001. Epub 2017 Jun 3. Actas Urol Esp (Engl Ed). 2018. PMID: 28587846 English, Spanish. No abstract available.
Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Anido Herranz U, Fernández Calvo O, Afonso Afonso FJ, Rodríguez Martínez de Llano S, Lázaro Quintela M, León Mateos L, Vázquez Estévez S, Antón Aparicio LM. Anido Herranz U, et al. Expert Rev Anticancer Ther. 2015 Mar;15(3):339-48. doi: 10.1586/14737140.2015.999045. Epub 2015 Jan 2. Expert Rev Anticancer Ther. 2015. PMID: 25555355 Free article. Review.
Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial.
Ferreiro-Pantín M, Anido-Herranz U, Betancor YZ, Cebey-López V, León-Mateos L, García-González J, García-Acuña SM, Fernández-Díaz N, Tubio JMC, López-López R, Ruiz-Bañobre J. Ferreiro-Pantín M, et al. Among authors: anido herranz u. ESMO Open. 2023 Aug;8(4):101611. doi: 10.1016/j.esmoop.2023.101611. Epub 2023 Jul 27. ESMO Open. 2023. PMID: 37516059 Free PMC article. Clinical Trial.
The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
Carretero-González A, Lora D, Martín Sobrino I, Sáez Sanz I, Bourlon MT, Anido Herranz U, Martínez Chanzá N, Castellano D, de Velasco G. Carretero-González A, et al. Among authors: anido herranz u. Cancers (Basel). 2020 Jul 17;12(7):1945. doi: 10.3390/cancers12071945. Cancers (Basel). 2020. PMID: 32709062 Free PMC article. Review.
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study.
Ruiz-Bañobre J, Molina-Díaz A, Fernández-Calvo O, Fernández-Núñez N, Medina-Colmenero A, Santomé L, Lázaro-Quintela M, Mateos-González M, García-Cid N, López-López R, Vázquez S, Anido-Herranz U. Ruiz-Bañobre J, et al. Among authors: anido herranz u. ESMO Open. 2021 Apr;6(2):100090. doi: 10.1016/j.esmoop.2021.100090. Epub 2021 Mar 16. ESMO Open. 2021. PMID: 33740735 Free PMC article.
A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma.
Betancor YZ, Ferreiro-Pantín M, Anido-Herranz U, Fuentes-Losada M, León-Mateos L, García-Acuña SM, Vaamonde-Rodríguez V, García-Pinel B, Cebey-López V, Villaverde-Viaño R, Lombardía-Rodríguez H, Kotrulev M, Fernández-Díaz N, Gomez-Tourino I, Fernández-Baltar C, García-González J, Tubio JMC, López-López R, Ruiz-Bañobre J. Betancor YZ, et al. Among authors: anido herranz u. Front Immunol. 2024 Apr 10;15:1374728. doi: 10.3389/fimmu.2024.1374728. eCollection 2024. Front Immunol. 2024. PMID: 38660294 Free PMC article.
Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors.
Abou Jokh Casas E, Pubul Núñez V, Anido-Herranz U, Del Carmen Mallón Araujo M, Del Carmen Pombo Pasín M, Garrido Pumar M, Cabezas Agrícola JM, Cameselle-Teijeiro JM, Hilal A, Ruibal Morell Á. Abou Jokh Casas E, et al. Among authors: anido herranz u. World J Gastroenterol. 2020 Apr 7;26(13):1513-1524. doi: 10.3748/wjg.v26.i13.1513. World J Gastroenterol. 2020. PMID: 32308351 Free PMC article.
Brain metastases from prostate adenocarcinoma.
Castro Gómez JE, Anido Herranz U, Carballo Castro A, Gómez Caamaóo A, León Mateos LA, Porto Vázquez C, López López R. Castro Gómez JE, et al. Among authors: anido herranz u. Clin Transl Oncol. 2009 Jan;11(1):63-4. doi: 10.1007/s12094-009-0313-2. Clin Transl Oncol. 2009. PMID: 19155207
18 results